SUVEN · NSE
Suven Life Sciences Limited
₹341.55
-2.37% (-₹8.3)
Prev. close
₹349.85
Volume
2,61,686
Delivery %
40.7%
As of
18 Sept 2026
Price history
No analyst calls on this stock in the last 90 days yet.
Explore by date range →Analyst opinions
Fundamentals
About Suven Life Sciences Limited
Suven Life Sciences Limited, a clinical-stage biopharmaceutical company, develops novel therapeutics for central nervous system disorders and unmet needs in mental health in India, the United States, Europe, and internationally. It engages in the development of Masupirdine (SUVN-502), a 5-HT6 receptor antagonist for the treatment of cognitive and neuropsychiatric symptoms of Alzheimer's disease; and Samelisant (SUVN-G3031), a histamine H3 receptor inverse agonist/antagonist for the treatment of narcolepsy with or without cataplexy and idiopathic hypersomnia. The company also develops Ropanicant (SUVN-911), an a4ß2 nicotinic acetylcholine receptor (nAChR) antagonist for the treatment of major depressive disorder; Usmarapride (SUVN-D4010), a 5-HT4 receptor partial agonist for management of cognitive dysfunction; and Tenaclidine (SUVN-I6107), a muscarinic M1 positive allosteric modulator for the treatment of cognitive disorders and schizophrenia. In addition, it is involved in the development of programs, such as SUVN-M8036 Serotonin/Dopamine Modulator for psychiatric disorder indications; SUVN-D1044 5-HT4 Agonist for gastrointestinal disorders; M4 PAM for psychosis indications; P2X7 Antagonist for pain and inflammation indications; Multimodal Dual 5-HT2A Antagonist and 5-HT1A Agonist for psychosis and depression indications; 5-HT1A Agonist for treatment resistant depression; Multimodal Dual 5-HT2A Antagonist and SRI for bipolar disorders, and depression and schizophrenia; and M1 PAM for gastrointestinal disorder indications. The company was formerly known as Suven Pharmaceuticals Pvt. Ltd. and changed its name to Suven Life Sciences Limited in 2003. The company was incorporated in 1989 and is based in Hyderabad, India. Suven Life Sciences Limited operates as a subsidiary of Jasti Property and Equity Holdings Private Limited.
Details
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Mr. Venkateswarlu Jasti M.Pharm. M.S.
Headquarters
Hyderabad
Employees
142
Website
suven.comExchange
View on NSE ↗Key stats
Market cap
₹9,735.70 Cr
EPS (TTM)
₹-14.60
Beta (1Y · daily vs NIFTY 50)
1.36
Beta (5Y · monthly vs NIFTY 50)
1.63
Shares float
7.50 Cr
EPS · quarter ended Jun 2026
₹-4.84
Financial Performance
01 · Financials
Revenue for Mar 2021–Mar 2022 is as filed with BSE (consolidated), and the first plotted growth figure is computed against Mar 2020 revenue as filed with BSE; the two sources' revenue definitions differ by 0.0% on Mar 2023. FY21 growth needs FY20 filings, which the data source doesn't provide.
02 · Earnings Per Share (EPS)
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based · pre-FY23 not filed in verifiable form
05 · Capital Structure & Asset Utilization
Pre-FY23 not filed in verifiable form
Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
Pre-FY23 not filed in verifiable form
07 · Debt Level & Coverage
Pre-FY23 not filed in verifiable form
08 · Profit & Loss
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹13.48 Cr | ₹11.84 Cr | ₹13.54 Cr | ₹11.69 Cr | ₹6.66 Cr | ₹7.11 Cr | |
| EBITDA | ₹-72.31 Cr | ₹-117.07 Cr | ₹-111.44 Cr | ₹-99.42 Cr | ₹-154.88 Cr | ₹-270.57 Cr |
| ₹-72.15 Cr | ₹-122.00 Cr | ₹-118.27 Cr | ₹-105.08 Cr | ₹-160.75 Cr | ₹-276.34 Cr | |
| Diluted EPS | ₹-5.67 | ₹-9.57 | ₹-6.63 | ₹-4.82 | ₹-7.37 | ₹-12.13 |
Total expenses (as filed), Employee benefit expense, Depreciation & amortisation, Other expenses, Other income have filed figures for only some of the years shown — no further verified source covers the rest, so those years are left blank rather than estimated.
09 · Balance Sheet
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| — | — | ₹388.91 Cr | ₹284.90 Cr | ₹135.18 Cr | ₹624.21 Cr | |
| — | — | ₹1.61 Cr | ₹70.97 L | ₹0 | ₹16.69 Cr | |
| Stockholders' equity | — | — | ₹375.32 Cr | ₹270.04 Cr | ₹109.99 Cr | ₹591.40 Cr |
Total assets, Current assets, Trade receivables, Cash & equivalents, Non-current assets, Fixed assets, CWIP, Others, Total debt, Long-term debt, Current (short-term) debt, Stockholders' equity have filed figures for only some of the years shown — no further verified source covers the rest, so those years are left blank rather than estimated. Inventory shows ₹0 for 2023-03-31 — a real filed figure, not a gap: positively consistent with a filer that holds no physical inventory (typical for lenders and other financial-services companies). 2021-03-31, 2022-03-31 have no Inventory figure at all reaching this deck yet — not verified as zero, not verified as positive — so they are left blank rather than assumed to match the filed zero.
Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.
10 · Cash Flow Statement
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹-132.71 Cr | ₹-127.54 Cr | ₹-115.98 Cr | ₹-82.62 Cr | ₹-154.10 Cr | ₹-301.79 Cr | |
| Investing cash flow | ₹92.53 Cr | ₹-22.23 Cr | ₹-247.81 Cr | ₹61.59 Cr | ₹154.95 Cr | ₹-462.11 Cr |
| ₹34.86 Cr | ₹145.69 Cr | ₹395.54 Cr | ₹-1.05 Cr | ₹-75.63 L | ₹757.15 Cr | |
| Capital expenditure | ₹-6.30 Cr | ₹-19.77 Cr | ₹-2.89 Cr | — | ₹-37.28 Cr | ₹-5.08 Cr |
| End cash position | ₹9.35 Cr | ₹5.27 Cr | ₹37.02 Cr | ₹14.93 Cr | ₹15.03 Cr | ₹8.28 Cr |
Depreciation & amortization, Dividends paid, Capital expenditure have filed figures for only some of the years shown — no further verified source covers the rest, so those years are left blank rather than estimated.
Annual only — the data source has no quarterly cash-flow-statement coverage.
11 · Shareholding Pattern
NSE, quarterly
| Line item | Sep 21–Dec 21(2Q) | Mar 22–Nov 22(5Q) | Dec 22–Mar 24(6Q) | Jun 24–Jun 25(5Q) | Jul 25 | Sep 25–Dec 25(2Q) | Mar 26–Mar 26(2Q) | Jun 26 | Jul 26 |
|---|---|---|---|---|---|---|---|---|---|
| Promoter | 60.00% | 64.98% | 69.57% | 70.27% | 67.43% | 67.36% | 70.15% | 70.08% | 65.47% |
| Public | 40.00% | 35.02% | 30.43% | 29.73% | 32.57% | 32.64% | 29.85% | 29.92% | 34.53% |
| Employee trusts | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Source: NSE quarterly shareholding-pattern filings, collapsed to periods where the reported percentages held steady — a column spanning several quarters means no change was filed across them. No FII/DII sub-split available from this source — Public includes all non-promoter, non-employee-trust holders.
12 · Peer Comparison
Healthcare
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4.48 L Cr | ₹1,837.3 | 37.0 | 5.36 | 13.7% | 0.06 | +11.9% | +11.4% |
| Divi's Laboratories Limited | ₹2.47 L Cr | ₹9,375 | 83.3 | 14.77 | 15.3% | 0.00 | +12.3% | +53.4% |
| Torrent Pharmaceuticals Limited | ₹1.83 L Cr | ₹4,875 | 76.9 | 21.82 | 25.8% | 1.79 | +21.5% | +37.4% |
| Apollo Hospitals Enterprise Limited | ₹1.26 L Cr | ₹8,944.5 | 60.4 | 13.30 | 20.5% | 0.90 | +15.7% | +13.9% |
| Lenskart Solutions Limited | ₹1.18 L Cr | ₹707.2 | 179.9 | 13.48 | 5.6% | 0.35 | +35.4% | — |
| Zydus Lifesciences Limited | ₹1.13 L Cr | ₹1,160 | 25.3 | 4.18 | 18.6% | 0.46 | +18.4% | +10.7% |
| Cipla Limited | ₹1.10 L Cr | ₹1,376.3 | 32.5 | 3.19 | 11.3% | 0.02 | +2.1% | -11.8% |
| Laurus Labs Limited | ₹1.05 L Cr | ₹1,954 | 96.4 | 19.86 | 16.8% | 0.48 | +22.0% | +111.6% |
| Max Healthcare Institute Limited | ₹1.01 L Cr | ₹1,049.3 | 69.8 | 9.39 | 13.4% | 0.32 | +19.0% | -10.6% |
| Dr. Reddy's Laboratories Limited | ₹97,876.16 Cr | ₹1,185 | 29.6 | 2.60 | 11.4% | 0.21 | +3.2% | -10.4% |
| Manipal Health Enterprises Limited | ₹97,364.22 Cr | ₹738.95 | 146.6 | 11.56 | 7.8% | 1.53 | +18.0% | — |
| Suven Life Sciences Limited | ₹9,748.41 Cr | ₹349.85 | — | 16.48 | -46.7% | 0.03 | +6.9% | +53.9% |
Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.
Documents
Annual reports
Show all 30
Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.
Index membership
4 indices
Weight is BSE’s own published index weight. Indices without weight data are listed without one, in alphabetical order after the weighted ones.